Taking a form of vitamin K2 called MK4, along with regular cancer treatment, slows down how fast liver cancer grows. This gives patients more time before the cancer gets worse.
See the scientific wording
Supplementation with vitamin K2 (menaquinone-4, MK4) when combined with standard cancer therapies reduces the progression of liver cancer in patients.
Very strong evidence
One moderate-quality study supports this claim, so treat this as an early signal rather than settled science.
What the research says
1 study reviewedSupporting (1)
Systematic Review With Meta-AnalysisMeta-analysis2026
The study found that taking vitamin K with regular cancer treatment helped slow down liver cancer growth and reduced the chance of it coming back, which supports the idea that it can slow progression.
Contradicting (0)
No contradicting studies found yet
That doesn't mean it's settled — it just means no study has tested the opposite.
Quality-weighted scoring: we follow the GRADE framework — each study is rated High, Moderate, Low, or Very Low based on study design, methodology rigor, and risk of bias. A single high-quality RCT can outweigh several weaker observational studies.
Scores reflect study quality, not just count.
Vitamin K2 slows liver cancer growth by blocking a signal that cancer cells use to grow and divide. It also turns on a brake that stops cells from multiplying. This causes cancer cells to stop dividing or die, which keeps the tumor from growing.
Score breakdown, mechanism chain, raw evidence, ideal studies needed & 1 supporting study
Related videos
How Fit Body Science checks a claim
- 1
We isolate the claim
Health advice from videos, articles and studies is broken down into single, testable claims.
- 2
We find the research
Each claim is matched against peer-reviewed studies, with every source cited by DOI.
- 3
We grade the evidence
Studies are scored on methodology, statistical rigor, transparency and publication quality.
The fitness and health internet is full of confident claims. We check them against real research.
Every claim on this site is traced back to peer-reviewed studies, scored on methodology and reporting quality, and given a verdict you can audit yourself — sources, DOIs and all.
- Full evidence breakdown and mechanism chains
- Ask our AI anything about a claim or its studies
- Get notified when new research changes a verdict
Taking a form of vitamin K2 called MK4, along with regular cancer treatment, slows down how fast liver cancer grows. This gives patients more time before the cancer gets worse.
Mechanism
1 studyVitamin K2 helps slow liver cancer by doing two things: it stops cancer cells from growing and dividing, and it also prevents the tumor from making new blood vessels. The main way is by turning off a growth signal and turning on a brake, so the cancer cells cannot multiply.
Vitamin K2 slows liver cancer growth by blocking a signal that cancer cells use to grow and divide. It also turns on a brake that stops cells from multiplying. This causes cancer cells to stop dividing or die, which keeps the tumor from growing.
Vitamin K2 inhibits the activity of IKK kinase, which prevents the phosphorylation and degradation of IκB, thereby keeping NF-κB in an inactive state.
Inactive NF-κB cannot enter the nucleus to turn on genes like cyclin D1, which is needed for the cell cycle to progress.
Vitamin K2 also inhibits protein kinase C (PKC) and PKD1, which further suppresses NF-κB activation and leads to activation of the protein kinase A pathway.
The protein kinase A pathway activates p53, which promotes transcription of p21, a cell cycle inhibitor that halts the cell cycle in cancer cells.
Vitamin K2 downregulates the expression of hepatocyte growth factor (HCC-derived growth factor), reducing signals that promote tumor growth and invasion.
Less supported by current evidence, but not ruled out
In a common treatment called TACE, blood supply to the tumor is blocked, but the tumor responds by making new blood vessels. Vitamin K2 stops this by blocking a key signal that makes new blood vessels, so the tumor cannot get the nutrients it needs to grow.
Transarterial chemoembolization (TACE) creates an ischemic and hypoxic microenvironment in the tumor.
Hypoxia upregulates pro-angiogenic factors such as HIF-1α and VEGF.
VEGF binds to VEGFR2 on endothelial cells, promoting angiogenesis.
Vitamin K2 selectively inhibits VEGFR2 phosphorylation, blocking downstream signaling and preventing angiogenesis rebound.
Evidence from Studies
Last searched 1mo ago
Supporting (1)
Community contributions welcome
The role of vitamin K in the prognosis of patients with hepatocellular carcinoma: a systematic review and meta-analysis
The study found that taking vitamin K with regular cancer treatment helped slow down liver cancer growth and reduced the chance of it coming back, which supports the idea that it can slow progression.
Contradicting (0)
Community contributions welcome
Score Breakdown
No multi-axis breakdown available yet. The overall Pro / Against score above is the best signal.
- No clinical evidence is available; the score reflects mechanistic plausibility only.
What Would Prove This
Per GRADE and EBM methodology, here is what ideal scientific evidence would look like to definitively prove or disprove this claim, ordered from strongest to weakest.
Systematic Review and Meta-Analysis of Vitamin K2 MK4 as Adjunctive Therapy for Liver Cancer
Comprehensive search of RCTs comparing vitamin K2 MK4 plus standard cancer therapy versus standard therapy alone in liver cancer patients, with meta-analysis of progression-free survival and overall survival outcomes.
Phase III Randomized Trial of Vitamin K2 MK4 Combined with Standard Chemotherapy for Liver Cancer
Randomized, placebo-controlled, double-blind trial in adult patients with unresectable liver cancer, receiving standard systemic therapy plus either vitamin K2 MK4 (e.g., 45 mg/day) or placebo, with progression-free survival as the primary endpoint over a 2-year period.
Prospective Cohort Study on Vitamin K2 MK4 Supplementation and Liver Cancer Outcomes
Prospective cohort of liver cancer patients receiving conventional therapies, with documented vitamin K2 MK4 supplement use, followed for progression-free and overall survival, adjusting for confounders like stage, treatment, and comorbidities.
Case-Control Study of Vitamin K2 MK4 Use and Liver Cancer Progression
Retrospective case-control study comparing liver cancer patients with slow progression (cases) to those with fast progression (controls), matching on stage, age, and treatment, and assessing vitamin K2 MK4 supplement use via interviews or records.
In Vitro Study of Vitamin K2 MK4 Effects on Liver Cancer Cell Proliferation
Treat liver cancer cell lines (e.g., HepG2, Huh7) with increasing concentrations of vitamin K2 MK4 (e.g., 0-100 µM) and assess cell viability, apoptosis, and proliferation over 48-72 hours.